Cargando…

2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome

BACKGROUND: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially risky invasive diagnostic procedures. RESULTS: We have performed an in dept...

Descripción completa

Detalles Bibliográficos
Autores principales: Heywood, Wendy E, Madgett, Tracey E, Wang, Darrell, Wallington, Amanda, Hogg, Julie, Mills, Kevin, Avent, Neil D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189872/
https://www.ncbi.nlm.nih.gov/pubmed/21929753
http://dx.doi.org/10.1186/1477-5956-9-56
_version_ 1782213515103174656
author Heywood, Wendy E
Madgett, Tracey E
Wang, Darrell
Wallington, Amanda
Hogg, Julie
Mills, Kevin
Avent, Neil D
author_facet Heywood, Wendy E
Madgett, Tracey E
Wang, Darrell
Wallington, Amanda
Hogg, Julie
Mills, Kevin
Avent, Neil D
author_sort Heywood, Wendy E
collection PubMed
description BACKGROUND: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially risky invasive diagnostic procedures. RESULTS: We have performed an in depth two-dimensional difference gel electrophoresis (2D DIGE) study to identify potential biomarkers. We have used maternal plasma samples obtained from first and second trimesters from mothers carrying DS affected fetuses compared with mothers carrying normal fetuses. Plasma samples were albumin/IgG depleted and expanded pH ranges of pH 4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9 were used for two-dimensional gel electrophoresis (2DE). We found no differentially expressed proteins in the first trimester between the two groups. Significant up-regulation of ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain H4, complement proteins C1s subcomponent, C4-A, C5, and C9 and kininogen 1 were detected in the second trimester in maternal plasma samples where a DS affected fetus was being carried. However, ceruloplasmin could not be confirmed as being consistently up-regulated in DS affected pregnancies by Western blotting. CONCLUSIONS: Despite the in depth 2DE approach used in this study the results underline the deficiencies of gel-based proteomics for detection of plasma biomarkers. Gel-free approaches may be more productive to increase the number of plasma biomarkers for DS for non-invasive prenatal screening and diagnosis.
format Online
Article
Text
id pubmed-3189872
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31898722011-10-11 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome Heywood, Wendy E Madgett, Tracey E Wang, Darrell Wallington, Amanda Hogg, Julie Mills, Kevin Avent, Neil D Proteome Sci Research BACKGROUND: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially risky invasive diagnostic procedures. RESULTS: We have performed an in depth two-dimensional difference gel electrophoresis (2D DIGE) study to identify potential biomarkers. We have used maternal plasma samples obtained from first and second trimesters from mothers carrying DS affected fetuses compared with mothers carrying normal fetuses. Plasma samples were albumin/IgG depleted and expanded pH ranges of pH 4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9 were used for two-dimensional gel electrophoresis (2DE). We found no differentially expressed proteins in the first trimester between the two groups. Significant up-regulation of ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain H4, complement proteins C1s subcomponent, C4-A, C5, and C9 and kininogen 1 were detected in the second trimester in maternal plasma samples where a DS affected fetus was being carried. However, ceruloplasmin could not be confirmed as being consistently up-regulated in DS affected pregnancies by Western blotting. CONCLUSIONS: Despite the in depth 2DE approach used in this study the results underline the deficiencies of gel-based proteomics for detection of plasma biomarkers. Gel-free approaches may be more productive to increase the number of plasma biomarkers for DS for non-invasive prenatal screening and diagnosis. BioMed Central 2011-09-19 /pmc/articles/PMC3189872/ /pubmed/21929753 http://dx.doi.org/10.1186/1477-5956-9-56 Text en Copyright ©2011 Heywood et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Heywood, Wendy E
Madgett, Tracey E
Wang, Darrell
Wallington, Amanda
Hogg, Julie
Mills, Kevin
Avent, Neil D
2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title_full 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title_fullStr 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title_full_unstemmed 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title_short 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
title_sort 2d dige analysis of maternal plasma for potential biomarkers of down syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189872/
https://www.ncbi.nlm.nih.gov/pubmed/21929753
http://dx.doi.org/10.1186/1477-5956-9-56
work_keys_str_mv AT heywoodwendye 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT madgetttraceye 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT wangdarrell 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT wallingtonamanda 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT hoggjulie 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT millskevin 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome
AT aventneild 2ddigeanalysisofmaternalplasmaforpotentialbiomarkersofdownsyndrome